Melanoma is considered Australia’s ‘national cancer’ and presents a significant disease burden to the Australian population.

Data and evidence emerging from clinical trials, research and clinical practice have driven significant changes across the care pathway for melanoma in the last 12 months. A series of new drugs and extended indications for systemic treatments for melanoma have also recently been approved, increasing the variety of treatment options for Australians living with melanoma.

Viewing this on mobile? Tell us what you thought. Complete the survey

Additional resources

Melanoma

  1. Melanoma Institute Australia

Skin cancer prevention

  1. Cancer Institute NSW
  2. Cancer Council

AYA

  1. Learn more about why Youth Cancer Services are needed.
  2. Refer to a Youth Cancer Service today.

irAEs

  1. eviQ: Management of immune related adverse events
  2. Immunotherapy patient assessment tool
  3. eviQ Education: Immune related adverse events module
References: 
  1. 1.    Australian Institute of Health and Welfare (AIHW) 2017. Cancer in Australia 2017, Cancer series no. 101. Cat. No. CAN 100. Canberra: AIHW. 6th March 2019 https://www.aihw.gov.au/getmedia/3da1f3c2-30f0-4475-8aed-1f19f8e16d48/20066-cancer-2017.pdf.aspx?inline=true

    2.    Australian Institute of Health and Welfare 2016. Australian Cancer Incidence and Mortality (ACIM) books: melanoma skin cancer. Canberra: AIHW. 4th March 2019 https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia/acim-books

    3.    Australian Institute of Health and Welfare (AIHW) 2018. Cancer Data in Australia, Cat. No. CAN 122. Canberra: AIHW. 5th March 2019 https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia/contents/incidence-and-survival-by-stage

    4.    Cancer Council Australia 2018. Clinical practice guidelines for the diagnosis and management of melanoma. Cancer Council. 8th March 2019 https://wiki.cancer.org.au/australia/Guidelines:Melanoma

    5.    Wolchok, J.D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.J., Cowey, C.L., Lao, C.D., Wagstaff, J., Schadendorf, D., Ferrucci, P.F. and Smylie, M., 2017. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. New England Journal of Medicine, 377(14), pp.1345-1356.

    6.    Australian Institute of Health and Welfare 2018. Cancer in adolescents and young adults in Australia. Cat. No. CAN 110. Canberra: AIHW. 7th March 2019 https://www.aihw.gov.au/getmedia/ed22109b-ab23-4273-8d23-7949a8922ea2/aihw-can-110.pdf.aspx?inline=true

    7.    Iannacone MR, Youlden DR, Baade PD, Aitken JF & Green AC 2015. Melanoma incidence trends and survival in adolescents and young adults in Queensland, Australia. International Journal of Cancer 136:603–9.

    8.    Haggar FA, Preen DB, Pereira G, Holman CDJ & Einarsdottir K 2012. Cancer incidence and mortality trends in Australian adolescents and young adults, 1982–2007. BMC Cancer 12:151.

    9.    Whiteman DC, Bray CA, Siskind V, Green AC, Hole DJ & MacKie RM 2008. Changes in the incidence of cutaneous melanoma in the west of Scotland and Queensland, Australia: hope for health promotion? European Journal of Cancer Prevention 17:243–50.

Create your own user feedback survey